Conference Reports for NATAP

Back

Infectious Disease Societyof America (IDSA) IDSA 49th Annual Meeting October 20-23, 2011Boston, MA     Lopinavir/ritonavir (LPV/r) Combined with Raltegravir (RAL) or Tenofovir/Emtricitabine (TDF/FTC) in Antiretroviral-Naïve Subjects: 96-Week Efficacy and Safety Results of the PROGRESS Study - (11/02/11)   A Seven-Year Review of AIDS and Non-AIDS related Malignancies in a Large HIV/AIDS Center in New York - (11/02/11)   Treatment of high grade anal lesions in high risk patients: outcome at an urban community health center - (11/02/11)   Risk of Muscle Breakdown in HIV - see slides below article - (11/01/11)   Prevalence and Patterns of Echocardiographic Abnormalities in HIV-Infected, Black Individuals in an Inner City Teaching Hospital in Washington DC - (11/01/11)   Peripheral mechanisms of CD4 T cell regeneration in HIV-1 elite controllers: naïve CD4s are severely depleted in elite controllers - (10/31/11)   Patterns of Use and Outcomes in Patients Treated with Etravirine in the HIV Research Network - (10/25/11)   Efficacy and hepatic safety of rilpivirine (RPV, TMC278) in treatment-naïve, HIV-1-infected patients co-infected with hepatitis B and/or C: pooled 96-week analysis of the Phase III ECHO and THRIVE trials - (10/25/11)   Analysis of lipid levels and neuropsychiatric events in treatment-naïve HIV-1-infected adults treated with rilpivirine or efavirenz over 96 weeks in ECHO and THRIVE - (10/25/11)   Boceprevir Plus Peginterferon/Ribavirin for the Treatment of HCV/HIV Co-Infected Patients - (10/25/11)   Rilpivirine Week 96 safety and efficacy by gender and race subgroups in treatment-naïve HIV-1-infected patients in the Phase III ECHO and THRIVE trials - (10/24/11)   Boceprevir Plus Peginterferon/Ribavirin for the Treatment of HCV/HIV Co-Infected Patients - (10/23/11)   Raltegravir (RAL)-based Therapy Demonstrates Superior Virologic Suppression and Immunologic Response Compared with Efavirenz (EFV)-based Therapy, with a Favorable Metabolic Profile, Through 4 Years in Treatment-naïve Patients: 192 Week Results from STARTMRK - (10/23/11)